Aditxt Signs a Definitive Agreement to Acquire Appili Therap

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...

Related Keywords

United States , Canada , Canadian , Don Cilla , Amro Albanna , Francisella Tularensis , Aditxt Inc , Nelson Mullins Riley Scarborough , Dentons Canada , Saptalis Pharmaceuticals , Richter Hampton , Appili Therapeutics Inc , Aird Berlis , Adivir Inc , World Health Organization , Appili Special Committee , Bloom Burton Co , Us National Institutes Of Health , Appili Therapeutics , Arrangement Agreement , Canada Business Corporations Act , Approved Taste Masked Oral Suspension , Live Attenuated Vaccine , Investigational New Drug , Priority Review Voucher , Medical Countermeasures , Topical Formulation , Cutaneous Leishmaniasis , Neglected Tropical Disease , Canada Business Corporations , Appili Shares , Appili Shareholder , Appili Share , Share Consideration , Appili Shareholders , Aditxt Shares , Transaction Aditxt , United States Securities Act , Nelson Mullins Riley , Bloom Burton , Appili Board , Appili Special , Promising Innovations Possible Together , Nasdaq Stock Market , Annual Report , Quarterly Report , Markets ,